Inhibiting angiogenesis by oral immunisation with poly(1-caprolactone)- poly(ethylene glycol)-poly(1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor
Abstract
Attempts to neutralise basic fibroblast growth factor (BFGF) have met some success in blocking neovascularisation. The authors describe an oral protein vaccine based on human BFGF encapsulated poly(e-caprolactone)epoly(ethylene glycol)epoly(e-caprolactone) (PCEC) nanoparticles. The human BFGF encapsulated PCEC nanoparticles (BFGF/PCEC) were monodisperse with the mean diameter of 142enm and can slow-released BFGF
in vitro
. After mice were...
Paper Details
Title
Inhibiting angiogenesis by oral immunisation with poly(1-caprolactone)- poly(ethylene glycol)-poly(1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor
Published Date
May 19, 2011
Journal
Volume
6
Issue
4
Pages
221 - 225
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History